SCHEMBL3966277

SCHEMBL3966277

Cc1cc(C)c(S(=O)(=O)Nc2ccc3c(-c4ccccc4Cl)n[nH]c3c2)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ GAA P10253 2/20 0.51
▸ MAP2K4 P45985 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MCOLN3 Q8TDD5 1/20 0.45
▸ MAPK8 P45983 2/20 0.44
▸ MAPK10 P53779 2/20 0.44
▸ MAPK14 Q16539 2/20 0.44
▸ SGK1 O00141 1/20 0.44
▸ TOP2A P11388 1/20 0.43
▸ TSHR P16473 2/20 0.43
▸ SLC40A1 Q9NP59 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ GFER P55789 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ NR1I2 O75469 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968707 0.90 MAP2K4 (0.47) MAP2K4LMNAMAPK8MAPK10MAPK14
SCHEMBL3964290 0.88 ALDH1A1 (0.53) GAAMAP2K4LMNAMAPK8MAPK10
SCHEMBL3964176 0.86 SGK1 (0.52) MAP2K4LMNAMAPK8MAPK10MAPK14
SCHEMBL3969942 0.86 MAP2K4 (0.54) MAP2K4LMNAMAPK8MAPK10MAPK14
SCHEMBL3969461 0.86 MEN1 (0.53) SMN1; SMN2GAAMAP2K4LMNASGK1
SCHEMBL3967750 0.84 MAP2K4 (0.56) MAP2K4MEN1KMT2A
SCHEMBL3973325 0.84 MAP2K4 (0.51) SMN1; SMN2MAP2K4LMNAMEN1KMT2A
SCHEMBL27721295 0.84 MAPK10 (0.45) MAP2K4MAPK8MAPK10MAPK14SGK1
SCHEMBL3966208 0.84 MAP2K4 (0.56) MAP2K4MAPK8MAPK10MAPK14SGK1
SCHEMBL3962444 0.84 SGK1 (0.61) MAP2K4MAPK8MAPK10MAPK14SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517901-B2 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC (US) 2009-04-14 — — US disclosed
US-7517901-B2 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC (US) 2009-04-14 — — US disclosed
US-7517901-B2 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC (US) 2009-04-14 — — US disclosed
US-20070049633-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-01 — — US disclosed
US-20070049633-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-01 — — US disclosed
US-20070049633-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049633-A1 p38 MAP kinase inhibitors and methods for using the same MAPK1, MAP3K1, MAP3K20 SMN1; SMN2 1600/4885GAA 3831/4885MAP2K4 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback